1. About Us

    image

    We are a world leading Institute focussing on identification of the causes and development of cures for chronic inflammatory diseases

  2. Research

    image

    Multidisciplinary research in immunology, inflammation and translational medicine

  3. Prize Studentships

    image

    Prize Studentships available within the Kennedy Institute

  4. Positions available

    image

    Opportunities to work within the Institute are regularly available

  5. Translational Medicine

    image

    The Institute seeks to translate basic science to the clinic

  6. OA Centre

    image

    The Centre aims to develop novel disease "markers" and therapies for patients with osteoarthritis and to create a national training resource for scientists and clinicians working within the OA field.

  7. Talks & Events

    image

    The Institute hosts regular seminars and events

  8. Contact us

    image

    The Institute is based on the Old Road Campus in Headington, Oxford

About the Institute

The Kennedy Institute is situated at the heart of the University of Oxford’s Old Road campus, a premier site for translational research in Oxford. The Institute houses basic and clinician scientists working in the areas of microbiome, immunology, inflammation and tissue biology and repair. We adopt a multidisciplinary approach, from basic biology, through models of disease to the development and testing of novel therapies in the clinic. There are strong links with clinical centres focussing on joint and bone diseases, inflammatory bowel disease and cancer. The Institute Director is Professor Fiona Powrie FRS.

News Highlights

Researchers at the Kennedy Institute of Rheumatology, NDORMS have identified a new target for treatment of particular inflammatory conditions, with the findings published this week in PNAS.
A new study led by researchers at the Kennedy Institute and published today in Immunity [LINK] sheds light on the drivers behind Inflammatory bowel disease (IBD) and suggests potential new targets for treatment of the condition.
block-content

Events

Date: 02 Sep 2015 to 04 Sep 2015
Venue: Natural History Museum, Oxford
Status: Registration open

OA Centre


The Centre aims to develop novel disease "markers" and therapies for patients with osteoarthritis and to create a national training resource for scientists and clinicians working within the OA field.

Notable Recent Publications

IRF5 controls both acute and chronic inflammation. Weiss M, Byrne AJ, Blazek K, Saliba DG, Pease JE, Perocheau D, Feldmann M, Udalova IA. Proc Natl Acad Sci U S A 2015

Granulocyte macrophage colony-stimulating factor-activated eosinophils promote interleukin-23 driven chronic colitis. Griseri T, Arnold IC, Pearson C, Krausgruber T, Schiering C, Franchini F, Schulthess J, McKenzie BS, Crocker PR, Powrie F. Immunity 2015; 43: 187-199

A mouse model of HIES reveals pro- and anti-inflammatory functions of STAT3. Steward-Tharp SM, Laurence A, Kanno Y, Kotlyar A, Villarino AV, Sciume G, Kuchen S, Resch W, Wohlfert EA, Jiang K, Hirahara K, Vahedi G, Sun HW, Feigenbaum L, Milner JD, Holland SM, Casellas R, Powrie F, O'Shea JJ. Blood 2014; 123:2978-2987

IRF5:RelA interaction targets inflammatory genes in macrophages. Saliba DG, Heger A, Eames HL, Oikonomopoulos S, Teixeira A, Blazek K, Androulidaki A, Wong D, Goh FG, Weiss M, Byrne A, Pasparakis M, Ragoussis J, Udalova IA. Cell Rep 2014; 8:1308-17

The alarmin IL-33 promotes regulatory T-cell function in the intestine. Schiering C, Krausgruber T, Chomka A, Frohlich A, Adelmann K, Wohlfert EA, Pott J, Griseri T, Bollrath J, Hegazy AN, Harrison OJ, Owens BM, Lohning M, Belkaid Y, Fallon PG, Powrie F. Nature 2014; 513:564-8

Polarized release of T-cell-receptor-enriched microvesicles at the immunological synapse. Choudhuri K, Llodra J, Roth EW, Tsai J, Gordo S, Wucherpfennig KW, Kam LC, Stokes DL, Dustin ML. Nature 2014; 507:118-23

No front page content has been created yet.